Sign inJoin
Company / Finance

Aclarion, Inc.

ACON · NASDAQ

Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.

FollowAdd to WatchlistAsk Question
NASDAQACONCoverage BootstrapHealthcare TechnologyDiagnosticsMedical Software
Latest ReportMay 13, 2026Aclarion: the $19M cash pile chasing a tiny Nociscan revenue lineView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Aclarion: the $19M cash pile chasing a tiny Nociscan revenue line

Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Aclarion, Inc.the $19M cash pile chasing a tiny Nociscan revenue lineMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Aclarion: the $19M cash pile chasing a tiny Nociscan revenue lineAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.NASDAQMay 13, 2026Research reportReadSlides